Beazer Homes USA, Inc. is selling $200 million worth of senior notes in a private offering. Proceeds from the notes, which are due in 2019, will replenish cash that was already used to fund prior redemptions and repurchases of its outstanding senior notes, according to a company statement.

Beazer Homes is a single-family homebuilder based in Atlanta, Ga. In late-August, a former executive was indicted on accounting fraud and conspiracy to commit securities fraud. Beazer reported a net loss of $59.5 million in the fourth quarter and a net loss of $39 million for the fiscal year. Comparatively, the firm reported a net gain of $33.87 million in 4Q09 and a net loss of $189.4 million for the fiscal year 2009.

A class action lawsuit was filed in the United States District Court for the District of Vermont on behalf of purchasers of Green Mountain Coffee Roasters, Inc. securities during the period from July 28, 2010, to September 29, 2010.

The complaint alleges that Green Mountain and certain of its officers violated the Securities Exchange Act of 1934 by not disclosing improper revenue recognition practices.

On September 28, 2010, Green Mountain reported that the U.S. Securities and Exchange Commission's Division of Enforcement is conducting an investigation and seeking documents relating to certain revenue recognition practices and the Company's relationship with one of its fulfillment vendors. Additionally, Green Mountain announced that as of June 26, 2010, there is a cumulative $7.6 million overstatement of pre-tax income due to an accounting error.

In reaction to the news, Green Mountain shares fell 16.08% to close at $31.06 on September 29, 2010.

If you purchased Green Mountain securities during the Class Period, you may, no later than November 29, 2010, file a motion with the Court to appoint you lead plaintiff. A lead plaintiff is a representative party that directs the litigation, and will be the movant that the Court determines to have the largest financial interest in the litigation with claims typical of those of other class members and the ability to adequately represent the class. Your share in any recovery will not be enhanced by serving as a lead plaintiff. You do not need to move for lead plaintiff to recover as an absent class member. You may retain Milberg LLP, or other attorneys, for this action, but do not need to retain counsel to recover as an absent class member. The complaint in this action was not filed by Milberg.

Founded in 1965, Milberg has offices in New York, Los Angeles, Tampa, and Detroit. The Firm has litigated landmark cases and recovered billions for shareholders and consumers. Our website has additional information: (www.milberg.com).

Lead Counsel for the Class has announced, pursuant to an Order of the United States District Court for the Southern District of New York, that a hearing in the class action entitled Fogarazzo, et al. v. Lehman Brothers, Inc., et al., No. 03 Civ.5194 (SAS) will be held on January 31, 2011, at 4:30 p.m., before The Honorable Shira A. Scheindlin, at the Daniel Patrick Moynihan U.S. Courthouse, 500 Pearl Street, Courtroom 15C, New York, New York 10007, for the purpose of determining (1) whether the proposed Settlement of the claims against the Settling Defendants in the Action for the sum of $6,750,000 in cash should be approved by the Court as fair, reasonable, and adequate to Members of the Class; (2) whether, thereafter, this Action should be dismissed with prejudice as regards the Settling Defendants pursuant to the terms and conditions set forth in the Settlement Agreement dated as of August 23, 2010; (3) whether the proposed plan to distribute the Settlement proceeds (the "Plan of Allocation") is fair, reasonable, and adequate, and therefore should be approved; and (4) whether the application of Lead Counsel for the payment of attorneys' fees and expenses incurred in connection with the Settlement involving the Settling Defendants, and reimbursement of Lead Plaintiffs' reasonable costs and expenses (including lost wages) directly related to their representation of the Class should be approved.

If you purchased or otherwise acquired shares of RSL Communications, Inc. common stock between April 30, 1999 and December 29, 2000, your rights may be affected by this Settlement.  If you have not received a detailed Notice of Proposed Settlement of Class Action, Motion for Attorneys' Fees and Settlement Fairness Hearing ("Notice") and a copy of the Proof of Claim and Release, you may obtain copies by mail: RSL Communications Securities Litigation, c/o Berdon Claims Administration LLC. P.O. Box 9014, Jericho NY 11753-8914; by toll-free phone: 800-766-3330; by fax: 516-9831-0810; or you can download a copy at www.berdonclaims.com.  If you are a Class Member, in order to share in the distribution of the Net Settlement Fund, you must submit a Proof of Claim and Release postmarked no later than February 22, 2011, establishing that you are entitled to recovery.

PLEASE DO NOT CONTACT THE COURT OR THE CLERK'S OFFICE REGARDING THIS NOTICE.  If you have any questions about the Settlement, you may contact Lead Counsel at: Curtis V. Trinko, Esq.; The Law Office of Curtis V. Trinko LLP; 16 West 46th Street, 7th Floor; New York, NY 10036; 212-490-9550; ctrinko@trinko.com; or go to the Claims Administrator's website: www.berdonclaims.com.

Valencia biotech firm MannKind Corp.'s stock fell 11% Thursday after reports that a former senior manager said he had uncovered potentially serious problems with clinical trials of the company's experimental insulin inhaler.

The Food and Drug Administration is reviewing the Afrezza inhaler and is expected to make a decision Dec. 29 on whether to approve it.

The former MannKind manager, John Arditi, filed a lawsuit against the company in New Jersey Superior Court, saying he was wrongfully fired after internal audits he conducted in November 2009 uncovered "potential fraud and scientific misconduct" involving Afrezza clinical trial data. The lawsuit, which was filed in September, was first reported on TheStreet.com.

Arditi, who worked in a MannKind facility in New Jersey, said in the lawsuit that he urged his superiors at the firm to report his findings to the FDA but that the company refused because "if the FDA was notified of these concerns, it might delay approval" of the inhaler.

MannKind addressed the lawsuit in its most recent quarterly earnings report, stating that the company had completed an internal investigation into Arditi's claims and had hired an outside firm to conduct an independent investigation.

"Neither investigation found any basis for his claims," MannKind said. "The company believes that the allegations in the complaint are without merit and intends to defend against them vigorously."

Matthew J. Pfeffer, MannKind's corporate vice president, said the company was working on a legal response to the lawsuit. MannKind has until Dec. 3 to file its response in court, Pfeffer said.

MannKind has yet to share with the FDA the findings of its internal investigation or of the independent investigation, he said.

Shares Radian Group Inc. tumbled Monday after the mortgage insurer announced a public offering of convertible notes and disclosed it received a government subpoena.

Radian said it's publicly offering up to $350 million in convertible senior notes due 2017. The underwriters have the option to buy an additional $52.5 million of notes. The company said it plans to enter in a "capped call" to prevent the dilution of its shares once the debt is converted to stock.

But that did little to ease investor concerns. The stock of the Philadelphia company dropped $1.16, or 12 percent, to $8.79 in early afternoon trading.

The company also said Monday in a Securities and Exchange Commission filing that it received a subpoena from the U.S. Department of Housing and Urban Development asking for information on the company's captive reinsurance.

Under certain so-called "captive reinsurance" programs, insurers and lenders share premium revenue but also split exposure to any losses when borrowers default. Insurers take the primary loss, and lenders bear secondary exposure up to certain limits, after which insurers are saddled with the additional losses.